bioRxivImmunologyPreprint
SARS-CoV-2 Envelope protein (E) binds and activates TLR2: A novel target for COVID-19 interventions
Abstract
In this study, we present a molecular characterization of the interaction between the SARS-CoV-2 envelope protein E with TLR2. We demonstrated that E protein interacts physically with TLR2 receptor in a specific and dose-dependent manner. Furthermore, we showed that this interaction is able to engage TLR2 pathway as demonstrated by its capacity to activate NF-{kappa}B transcription factor and to stimulate the production of CXCL8 inflammatory chemokine in a TLR2-dependent manner. Furthermore, in agreement with the importance of NF-{kappa}B in TLR signaling pathway, we showed that the chemical inhibition of this transcription factor led to significant inhibition of CXCL8 production, while blockade of P38 and ERK1/2 MAP kinases resulted only in a partial CXCL8 inhibition. Overall, our findings suggest considering the envelope protein E as a novel target for COVID-19 interventions: (i) either by exploring the therapeutic effect of anti-E blocking/neutralizing antibodies in symptomatic COVID-19 patients, or (ii) as a promising non-Spike SARS-CoV-2 antigen candidate to include in the development of next generation prophylactic vaccines against COVID-19 infection and disease. ImportanceAlthough, the exact mechanisms of COVID-19 pathogenesis are unknown, recent data demonstrated that elevated levels of pro-inflammatory cytokines in serum is associated with enhanced disease pathogenesis and mortality. Thus, determining the molecular mechanisms responsible for inflammatory cytokine production in the course of SARS-CoV-2 infection could provide future therapeutic targets. In this context, to the best of our knowledge, our report is first to use a detailed molecular characterization to demonstrate that SARS-CoV-2 Envelope E protein binds to TLR2 receptor. Specifically, we showed that SARS-CoV-2 Envelope E protein binds to TLR2 in a direct, specific and dose-dependent manner. Investigating signalling events that control downstream activation of cytokine production show that E protein / TLR2 binding leads to the activation of NF-{kappa}B transcription factor that control the expression of multiple pro-inflammatory cytokines including CXCL8. Overall, our findings suggest considering the envelope protein E as a novel target for COVID-19 interventions.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway
S. Khan, M. S. Shafiei, … H. Zaki·bioRxiv·Mar 16, 2021
- Surface proteins of SARS-CoV-2 drive airway epithelial cells to induce interferon-dependent inflammation
G. Anand, A. M. Perry, … A. L. Steed·bioRxiv·Dec 14, 2020
- SARS-CoV-2 spike protein induces the cytokine release syndrome by stimulating T cells to produce more IL-2
- SARS-CoV-2 (E)-protein induces rapid TLR2-mediated T cell activation in mouse lungs revealed by intravital lung microscopy
Yasmin Shaalan, Nethaji Kuruppu, … Markus Rehberg·European Respiratory JournalPeer-reviewed·Jun 18, 2026
- SARS-CoV-2 Nsp14 activates NF-κB signaling and induces IL-8 upregulation
T.-W. Li, A. D. Kenney, … J. Zhu·bioRxiv·May 26, 2021
- SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB
C. J. Neufeldt, B. Cerikan, … R. Bartenschlager·bioRxiv·Jul 21, 2020